Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer.
Huiping LiGuohong SongQiaoxia ZhouRan RanHanfang JiangRuyan ZhangYaxin LiuJiayang ZhangLuping MengLiandong MaYe SunMeiyu WangQingqing ZhouHonghua YanQianxiang ZhouXunwei DongYouzhi TongPublished in: Breast cancer research and treatment (2021)
GT0918 can effectively inhibit AR-positive breast cancer tumor growth. GT0918 was demonstrated well tolerated with a favorable PK profile. The suitable dose of GT0918 was 500 mg QD and may provide clinical benefits for AR-positive mBC.